Phosphagenics Announce Positive Phase 1 Clinical Trial Results for Transdermal Lidocaine
News Dec 11, 2008
Phosphagenics Limited has announced the successful completion of a phase 1 clinical trial that examined the ability of its patented drug delivery system, TPM, to topically deliver the pain relief drug, lidocaine, safely into humans.
The trial demonstrated that the patented lidocaine formulation was able to deliver a greater amount of lidocaine into the localized area of the skin compared to a leading commercial product, Phosphagenics explains.
Lidocaine is a well known topical anaesthetic, sales of which exceeded US $1.2 billion in 2007. It is used for a wide variety of ailments, including temporary relief of rashes, stings, sprains, strains, bites, and burns.
This clinical trial compared the dermal penetration and measured the systemic exposure of lidocaine between one of the leading marketed products, Xylocaine® (5% lidocaine), and Phosphagenics’ TPM/lidocaine (5% lidocaine).
Dr Esra Ogru, Executive Vice President of Research and Development at Phosphagenics said; “While we have previously demonstrated the penetrative power of our TPM technology, the success of this trial validates the versatility and precision of Phosphagenics’ drug delivery platform in humans. We view this as a major achievement for our company and look forward to moving ahead with further clinical trials.”
The open label, single centre study was conducted at the Centre for Pharmaceutical Research, University of South Australia, under the guidance of Principal Investigator Dr. David Foster. 11 healthy adult volunteers enrolled in the bioavailability trial of dermal and systemic pharmacokinetics, which incorporated secondary endpoints of safety and tolerability.
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
3-D Tissue Model of Developing Heart Could Aid Drug Safety Testing for Pregnant WomenNews
The heart is the first organ to develop in the womb and the first cause of concern for many parents. Parents and doctors often have to consider the mother's health as well as the potential risk regarding how medication could affect their baby."We can try to rebuild the shape of the early development heart in the lab," said Professor Zhen Ma. "It mimics the very early stage, during the embryo genesis - how the heart was formed."READ MORE
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018